Pharmaceutical translation in Belgium: regulatory precision from clinical trial to market authorisation
Pharmaceutical documents are among the most consequential texts a translation agency handles. A submission to the European Medicines Agency, a clinical trial protocol, a patient information leaflet or a labelling file each carries regulatory and safety implications that tolerate no approximation. The terminology must be correct. The format must comply with the applicable guideline. The translation must be verifiable.
Pharmaceutical translation in Belgium operates within a dense regulatory framework: the Federal Agency for Medicines and Health Products (FAMHP/AFMPS), the European Medicines Agency (EMA), ICH guidelines, EU Clinical Trials Regulation (CTR 536/2014) and the MDR 2017/745 for pharmaceutical-adjacent medical devices. Every document must reflect the terminology validated by the relevant regulator, in the language it will be submitted in. BeTranslated, a specialised translation agency based in Liège, structures each pharmaceutical translation project around these regulatory requirements.
To request a quote, submit your files online.
Why pharmaceutical translation requires specialist expertise
Regulatory terminology is not optional
The EMA and FAMHP publish approved terminology for pharmacological concepts, dosing instructions, adverse event reporting and safety terminology in each of the EU’s official languages. A translation that deviates from this approved terminology, even subtly, may be rejected or returned for revision, delaying an authorisation process by months. The translator must know not only the language but the exact terms that the regulator expects to see in each section of the dossier.
Patient safety starts with clear communication
Patient information leaflets (PILs) and summary of product characteristics (SmPCs) are read by pharmacists, healthcare professionals and patients who act on them directly. A misrendered dosing instruction, a confusingly translated contraindication or an unclear adverse event description can contribute to medication errors. Belgium’s obligations under Directive 2001/83/EC require that PILs be legible, understandable and written in the official language of the member state where the product is marketed.
Pharmaceutical documents we translate
- Marketing authorisation applications (CTD, Common Technical Document)
- Clinical trial protocols and amendments (EudraCT, CTR)
- Informed consent forms and participant information sheets
- Pharmacovigilance reports (PSUR, DSUR, SUSAR, PADER)
- Patient information leaflets (PILs) and summaries of product characteristics (SmPCs)
- Labelling and packaging text in compliance with Annex II formats
- Regulatory correspondence with the FAMHP and the EMA
- Clinical study reports (CSR) submitted to regulatory bodies
- Quality and manufacturing documentation (GMP, validation reports)
Belgium’s pharmaceutical sector and its translation demands
Pharmaceutical and chemical products represent 25.9% of Belgium’s exports — €90 billion in 2024
Belgium is home to Janssen Pharmaceutica, UCB, Galapagos and among the largest pharma clusters in Europe
According to the SPF Economy, pharmaceutical and chemical products are Belgium’s single largest export category, reaching €90 billion in 2024 (25.9% of total goods exports). Major players including Janssen Pharmaceutica (Johnson & Johnson), UCB, Galapagos, GSK Vaccines and Pfizer all have significant Belgian operations. Each clinical trial conducted in Belgium, each product authorised by the FAMHP, and each label printed for the Belgian market generates pharmaceutical documentation that must be translated accurately into the relevant official languages.
Three languages, three regulatory audiences
Products marketed in Belgium must carry labelling and product information in French, Dutch and German. For clinical trial submissions under the EU CTR, the trial protocol and consent forms must be translated into the language of each participating member state. Managing this multilingual obligation for a multinational trial or a Belgian licensing dossier requires a translation partner with both language coverage and regulatory expertise.
How BeTranslated handles pharmaceutical translation
Linguists with pharmaceutical and regulatory backgrounds
Pharmaceutical files are assigned to linguists with academic or professional backgrounds in pharmacy, biochemistry, regulatory affairs or clinical research. Several have worked as regulatory affairs officers or medical writers before transitioning to translation. All translate into their mother tongue. Profiles are available on the professional translators page.
Independent review, ISO 17100 and confidentiality
Every pharmaceutical translation undergoes independent proofreading by a second specialist (ISO 17100). Confidential clinical data and unpublished compound information are handled under strict non-disclosure agreements and full GDPR compliance. Rates are quoted in a detailed proposal before project launch.
A regulatory dossier, PIL or clinical trial document to translate?
Request a quote with your files. A specialist project manager responds within 24 working hours.
Protect your regulatory submissions with specialist expertise
Whether you are a regulatory affairs manager preparing a CTD submission, a clinical operations director running a Belgian trial site or a medical writer producing a CSR, the quality of your pharmaceutical translation has direct consequences for the regulatory timeline and the safety of the patients your product is designed to serve.
To start your project, three routes are available:
- Submit your files via the online quote form
- Call +32 485 85 30 89
- Email hello@betranslated.be
Language combinations available in French, Dutch, German, English and all other languages on the languages page.
